R1 RCM (NASDAQ:RCM) Given Neutral Rating at Cantor Fitzgerald

R1 RCM (NASDAQ:RCM)‘s stock had its “neutral” rating reaffirmed by Cantor Fitzgerald in a research note issued to investors on Friday, Benzinga reports. They presently have a $14.30 price objective on the healthcare provider’s stock. Cantor Fitzgerald’s price objective suggests a potential upside of 0.78% from the company’s previous close.

Several other analysts also recently commented on RCM. Leerink Partners downgraded R1 RCM from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $17.00 to $14.30 in a research note on Thursday, August 1st. TD Cowen restated a “hold” rating and set a $14.30 price objective (down previously from $20.00) on shares of R1 RCM in a report on Monday, August 5th. Royal Bank of Canada reiterated an “outperform” rating and issued a $19.00 target price on shares of R1 RCM in a report on Friday, June 28th. Morgan Stanley lowered shares of R1 RCM from an “overweight” rating to an “equal weight” rating in a research note on Thursday, August 8th. Finally, Stephens lowered shares of R1 RCM from an “overweight” rating to an “equal weight” rating in a research note on Thursday, August 1st. Thirteen analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $15.41.

R1 RCM Trading Up 0.1 %

Shares of RCM stock opened at $14.19 on Friday. R1 RCM has a fifty-two week low of $8.87 and a fifty-two week high of $15.12. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.84 and a current ratio of 1.84. The stock has a 50 day simple moving average of $14.01 and a two-hundred day simple moving average of $13.04. The company has a market cap of $5.98 billion, a P/E ratio of -177.38 and a beta of 0.85.

R1 RCM (NASDAQ:RCM) last released its earnings results on Wednesday, August 7th. The healthcare provider reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.03. The company had revenue of $627.90 million for the quarter, compared to the consensus estimate of $633.10 million. R1 RCM had a negative net margin of 1.68% and a negative return on equity of 1.44%. The company’s revenue was up 12.0% compared to the same quarter last year. Research analysts forecast that R1 RCM will post -0.24 earnings per share for the current year.

Hedge Funds Weigh In On R1 RCM

Several institutional investors and hedge funds have recently bought and sold shares of RCM. Capital International Investors boosted its position in R1 RCM by 0.8% during the fourth quarter. Capital International Investors now owns 8,343,199 shares of the healthcare provider’s stock worth $88,188,000 after purchasing an additional 67,485 shares during the period. Sea Cliff Partners Management LP bought a new stake in R1 RCM during the 4th quarter valued at $18,459,000. First Light Asset Management LLC purchased a new stake in shares of R1 RCM during the fourth quarter worth $8,625,000. Caas Capital Management LP bought a new position in shares of R1 RCM in the fourth quarter worth $148,000. Finally, Bridgefront Capital LLC grew its position in shares of R1 RCM by 213.6% in the fourth quarter. Bridgefront Capital LLC now owns 32,266 shares of the healthcare provider’s stock valued at $341,000 after purchasing an additional 21,978 shares in the last quarter. 61.10% of the stock is owned by institutional investors.

R1 RCM Company Profile

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.